TNFRSF4 antibody
-
- Target See all TNFRSF4 Antibodies
- TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
-
Reactivity
- Mouse
-
Host
- Rat
-
Clonality
- Monoclonal
-
Conjugate
- This TNFRSF4 antibody is un-conjugated
-
Application
- Flow Cytometry (FACS), Immunofluorescence (IF)
- Characteristics
- Monoclonal Anti-Mouse CD134 is recommended for use in flow cytometry for identification of CD134 also known as OX-40.
- Immunogen
- Recombinant mouse OX-40-CD4 chimeric protein Species
- Clone
- OX-86
- Isotype
- IgG1
- Top Product
- Discover our top product TNFRSF4 Primary Antibody
-
-
- Application Notes
- It is recommended for use in flow cytometry. This reagent is effective for direct immunofluorescence staining of mouse tissue for flow cytometric analysis using 1 µg/10^6 cells
- Comment
-
Purified, unconjugated.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- The conjugate is provided in liquid form in buffer containing 1% bovine serum albumin (BSA) and 0,09% Sodium azide, pH 7.2.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C
-
- Target
- TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
- Alternative Name
- CD134 (TNFRSF4 Products)
- Synonyms
- TNFRSF4 antibody, ACT35 antibody, CD134 antibody, Ly-70 antibody, Ox40 antibody, TXGP1L antibody, Txgp1 antibody, OX40 antibody, TNF receptor superfamily member 4 antibody, tumor necrosis factor receptor superfamily, member 4 antibody, TNFRSF4 antibody, Tnfrsf4 antibody
- Background
- CD134 is a type I integral membrane protein also known as OX-40, ACT35, and tumor necrosis factor receptor superfamily member 4 (TNFRSF4). This receptor is expressed on activated CD4+ and CD8+ T cells and B cells. The OX-40 receptor binds to the OX-40 ligand (CD252) to provide a costimulatory signal that is independent of CD28. Blockade of OX40-OX40 ligand interactions has been shown to ameliorate experimental EAE and inflammatory bowel disease, which implies that these interactions are important in the pathogenesis of some autoimmune diseases.
- Pathways
- Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
-